<DOC>
	<DOCNO>NCT00119587</DOCNO>
	<brief_summary>The purpose study compare week every week darbepoetin alfa change hemoglobin level screening/baseline period evaluation period ( week 25-30 ) . This study also assess change mean hemoglobin 4 week interval , instability hemoglobin concentration , darbepoetin alfa dosing requirement red blood cell transfusion .</brief_summary>
	<brief_title>Darbepoetin Alfa Treatment Anemia Hemodialysis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Receiving hemodialysis least 6 month screen Clinically stable judge investigator Stable IV rHuEPO therapy administer 1 , 2 3 time per week least 8 week screen ( stable define less equal 25 % change [ ] weekly dose change frequency 8 week ) Adequate iron store ( serum ferritin great equal 100Î¼g/L ) screening period Available follow assessment Before study specific procedure carry , subject , his/her legally acceptable representative must give informed consent participation study Treatment grand mal epilepsy last 6 month Congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) Uncontrolled hypertension , define predialysis diastolic blood pressure measurement great equal 110mmHg screening period Clinical evidence current uncontrolled hyperparathyroidism ( e.g. , serum parathyroid hormone great 1500pg/mL ) within past 12 month Major surgery within 3 month screen ( excludes vascular access surgery ) Previously diagnose HIV chronic hepatitis B infection Clinical evidence current malignancy exclude basal cell squamous cell carcinoma skin Systemic hematological disease ( e.g. , sickle cell anemia , myelodysplastic syndrome , hematological malignancy ) ; myeloma ; hemolytic anemia Alanine transaminase ( ALT ) aspartate transaminase ( AST ) great 2 time upper limit normal range RBC transfusion ( ) within 12 week screen screening/baseline period , active bleed Clinical evidence current systemic infection Androgen therapy within 12 week screen No prior treatment darbepoetin alfa Currently enrol , yet complete period least 30 day since end , investigational device drug trial ( ) . Subjects receive investigational agent ( ) may enter study discussion agreement Amgen Pregnancy ( woman childbearing potential must use adequate contraception ) Breast feed Psychiatric , addictive , disorder compromise ability give truly informed consent likely alter compliance Anticipating schedule livingrelated kidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Amgen</keyword>
</DOC>